Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study
| Condition | Intervention | Phase |
|---|---|---|
|
Hematological Malignancies |
Procedure: Mesenchymal stem cell infusion |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study |
- Day-100 incidence of non-relapse mortality [ Time Frame: 100 days ] [ Designated as safety issue: Yes ]
- 1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution [ Time Frame: 365 days ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 30 |
| Study Start Date: | December 2006 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
MSC co-infusion with either HLA-mismatched PBSC or cord blood
|
Procedure: Mesenchymal stem cell infusion
Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
Other Name: Mesenchymal stem cells
|
Eligibility| Ages Eligible for Study: | up to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
V.1. Patients
V.1.1. Diseases
Hematological malignancies confirmed histologically and not rapidly progressing:
- AML in CR;
- ALL in CR;
- CML unresponsive/intolerant to Imatinib but not in blast crisis;
- Other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis;
- MDS with < 5% blasts;
- Multiple myeloma;
- CLL;
- Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);
- Hodgkin's disease.
V.1.2. Clinical situations
Theoretical indication for a standard allo-transplant, but not feasible because:
- Age > 55 yrs;
- Unacceptable end organ performance;
- Patient's refusal.
- Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.
V.1.3. Other inclusion criteria
- Male or female; fertile female patients must use a reliable contraception method;
- Age < 75 yrs.
- Informed consent given by patient or his/her guardian if of minor age.
V.1.4. Exclusion criteria
- Any condition not fulfilling inclusion criteria;
- HIV positive;
- Terminal organ failure, except for renal failure (dialysis acceptable);
- Uncontrolled infection, arrhythmia or hypertension;
- Previous radiation therapy precluding the use of 2 Gy TBI;
- HLA-identical donor.
V.2. PBSC donors
V.2.1. Inclusion criteria
- Related to the recipient (sibling, parent or child) or unrelated;
- Male or female;
- Weight > 15 Kg (because of leukapheresis);
- Fulfills generally accepted criteria for allogeneic PBSC donation;
- Informed consent given by donor or his/her guardian if of minor age, as per donor center standard procedures.
V.2.2. Exclusion criteria
- Any condition not fulfilling inclusion criteria;
- HIV positive;
- Unable to undergo leukapheresis because of poor vein access or other reasons.
V.2.3. HLA matching
Related or unrelated donors who have 1-2 HLA mismatches, as either :
- One antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1
- One allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1
- Two allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1
- One antigenic mismatch + 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1.
- One antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B or -C or -DRB1
V.3. Cord blood unit
Banked cord blood units will be used if they fulfill the following criteria:
- No more than 2/6 HLA mismatches (antigenic mismatch at HLA-A or HLA-B or allelic mismatch at HLA-DRB1)
- > 2.5 x 107 TNC/kg
- Standard validation by FACT/Netcord criteria.
Contacts and Locations| Belgium | |
| CHU Sart Tilman | |
| Liege, Belgium, 4000 | |
| Principal Investigator: | Frederic Baron, MD, PhD | CHU-ULg |
| Principal Investigator: | Yves Beguin, MD, PhD | CHU-ULg |
| Study Chair: | Chantal Lechanteur, PhD | CHU-ULg |
| Study Chair: | Etienne Baudoux, MD | CHU-ULg |
| Study Chair: | Evelyne Willems, MD | CHU-ULg |
More Information
No publications provided by University Hospital of Liege
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Yves Beguin, Prof, University Hospital of Liege |
| ClinicalTrials.gov Identifier: | NCT00504803 History of Changes |
| Other Study ID Numbers: | TJB0601 |
| Study First Received: | July 19, 2007 |
| Last Updated: | September 1, 2011 |
| Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines |
Keywords provided by University Hospital of Liege:
|
HCT, nonmyeloablative, mesenchymal stem cells, GVHD |
Additional relevant MeSH terms:
|
Neoplasms Graft vs Host Disease Hematologic Neoplasms |
Immune System Diseases Neoplasms by Site Hematologic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013